Metformin and Aging: What the Completed AMHM Trial Tested

TL;DR: This was a completed Phase 3, double-blind, placebo-controlled trial in 166 adults without type 2 diabetes. It tested whether metformin's effects depend on a person's baseline metabolic health. Results have been posted to the registry, but this explainer describes only what the study was designed to test — not what it concluded.

What the metformin aging trial actually tested

Metformin is a widely used, inexpensive drug that lowers blood sugar in people with type 2 diabetes. Because it also affects cellular energy pathways, researchers have long wondered whether it could slow aspects of biological aging — the gradual decline in function that raises the risk of many chronic diseases.

The Antecedent Metabolic Health and Metformin Aging Study (AMHM) asked a more specific and unusual question: does metformin help everyone equally, or do its effects depend on where you start? The investigators hypothesized that metformin might *improve* insulin sensitivity in people who are insulin resistant, while potentially *reducing* it in people who are already insulin sensitive. "Insulin sensitivity" refers to how efficiently your cells respond to insulin to take up glucose; poor sensitivity ("insulin resistance") is an early step toward metabolic disease.

How the study was designed

This was an interventional Phase 3 trial run at two sites — the Oklahoma Medical Research Foundation and the University of Wisconsin–Madison — enrolling 166 participants aged 40 to 75, of any sex, who did not have type 2 diabetes. Healthy volunteers were accepted.

Participants were first classified as insulin sensitive or insulin resistant. Within each group, half received metformin and half received a placebo tablet over a 12-week course, with neither participants nor researchers knowing who got which (double-blind). Before and after, the team measured insulin sensitivity, glucose regulation, mitochondrial function (mitochondria are the energy-producing structures in cells), and biomarkers of aging. The trial ran from July 2020 to March 2025.

Is metformin approved as an anti-aging drug?

No. Metformin is approved to manage type 2 diabetes, not to slow aging or extend healthspan. Using it for longevity remains investigational, which is exactly why trials like this exist. You can read more about the wider field of longevity pharmacology including metformin and rapamycin.

Frequently asked questions